Regular Article
Prediction of Inter-individual Variability in the Pharmacokinetics of CYP2C19 Substrates in Humans

https://doi.org/10.2133/dmpk.DMPK-13-RG-137Get rights and content

Summary:

Significant inter-individual variability of exposure for CYP2C19 substrates may be only partly due to genetic polymorphism. Therefore, the in vivo inter-individual variability in hepatic intrinsic clearance (CLint,h) of CYP2C19 substrates was estimated from reported AUC values using Monte Carlo simulations. The coefficient of variation (CV) for CLinth in poor metabolizers (PM) expected from genotypes CYP2C19*2/*2, CYP2C19*3/*3 or CYP2C19*2/*3 was estimated as 25.8% from the CV for AUC of omeprazole in PMs. With this, CVs of CLinth in extensive metabolizers (EM: CYP2C19*1/*1), intermediate metabolizers (IM: CYP2C19*1/*2 or *3) and ultra-rapid metabolizers (UM), CYP2C19*17/*17 and *1/*17, were estimated as 66.0%, 55.8%, 6.8% and 48.0%, respectively. To validate these CVs, variability in the AUC of CYP2C19 substrates lansoprazole and rabeprazole, partially metabolized by CYP3A4 in EMs and IMs, were simulated using the CV in CLjnt,h for CYP2C19 EMs and IMs and 33% of the CV previously reported for CYP3A4. Published values were within 2.5-97.5 percentile range of simulated CVs for the AUC. Furthermore, simulated CVs for the AUC of omeprazole and lansoprazole in ungenotyped populations were comparable with published values. Thus, estimated CLint,h variability can predict variability in the AUC of drugs metabolized not only by CYP2C19 but also by multiple enzymes.

References (54)

  • H.A. Dugger et al.

    Bioequivalence evaluation of lansoprazole 30-mg capsules (Lanfast® and Lanzor®) in healthy volunteers

    Eur. J. Pharm. Biopharm.

    (2001)
  • D. Tomalik-Scharte et al.

    The clinical role of genetic polymorphisms in drug-metabolizing enzymes

    Pharmacogenomics

    (2007)
  • T. Furuta et al.

    Individualized therapy for Gastroesophageal Reflux Disease: Potential impact of pharmacogenetic testing based on CYP2C19

    Mol. Diagn. Ther

    (2012)
  • T. Furuta et al.

    CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and Gastroesophageal Reflux Diseases with a proton pump inhibitor

    Pharmacogenomics

    (2007)
  • D. Sibbing et al.

    Cytochrome 2C19* 17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement

    Circulation

    (2010)
  • K.E. Thummel et al.

    Design and optimization of dosage regimens: pharmacokinetic data

  • K.E. Thummel et al.

    Design and optimization of dosage regimens: pharmacokinetic data

  • K.E. Thummel et al.

    Design and optimization of dosage regimens: pharmacokinetic data

  • M.S. Roberts et al.

    Correlation between in-vitro micro-somal enzyme activity and whole organ hepatic elimination kinetics: analysis with a dispersion model

    J. Pharm. Pharmacol.

    (1986)
  • Y. Naritomi et al.

    Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro

    Drug Metab. Dispos.

    (2003)
  • T. Uchimura et al.

    Prediction of human blood-to-plasma drug concentration ratio

    Biopharm. Drug Dispos.

    (2010)
  • S. Yasuda et al.

    Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers

    Int. J. Clin. Pharmacol. Ther

    (1994)
  • H.A. Wynne et al.

    The effect of age upon liver volume and apparent liver blood flow in healthy man

    Hepatology

    (2005)
  • A.L.M. Kerremans et al.

    Pharmacokinetic and pharmacodynamic studies of tienilic acid in healthy volunteers

    Eur. J. Clin. Pharmacol.

    (1982)
  • J.C. Gorski et al.

    In vivo effects of interleukin-10 on human cytochrome P450 activity

    Clin. Pharmacol. Ther.

    (2000)
  • H. Pirttiaho et al.

    Hepatic blood flow and drug metabolism in patients on enzyme-inducing anticonvulsants

    Eur. J. Clin. Pharmacol.

    (1982)
  • D. Davis et al.

    The effects of age and smoking on the plasma protein binding of lignocaine and diazepam

    Br. J. Clin. Pharmacol.

    (2012)
  • Cited by (18)

    • Prediction of inter-individual variability on the pharmacokinetics of CYP2C8 substrates in human

      2017, Drug Metabolism and Pharmacokinetics
      Citation Excerpt :

      Our group has previously proposed a method that uses the Monte Carlo simulation to predict the inter-individual variability in pharmacokinetics from the mean value and standard deviation (SD) of physiological and pharmacokinetic parameters collected from the literature. This method was successfully applied to predict the inter-individual variability in the pharmacokinetics of CYP1A2 [16], CYP2C9 [17], CYP2C19 [18], CYP2D6 [19,20], and CYP3A4 [21] substrates in healthy volunteers. In the case of CYP1A2, CV of CLint,h,1A2 was estimated from the clinical pharmacokinetic data of caffeine, which is a CYP1A2 substrate with high fmCYP1A2 and low hepatic first-pass effect.

    • Estimation of Interindividual Variability of Pharmacokinetics of CYP2C9 Substrates in Humans

      2017, Journal of Pharmaceutical Sciences
      Citation Excerpt :

      They collected the CVs reported for CYP3A4 content in human liver microsomes (33%-99%); based on a dispersion model for the in vivo variability of the area under the blood concentration curve (AUC) for the substrates and other physiological parameters (i.e., blood flow rate, plasma protein binding, liver volume, and body weight), they determined a CV of 33% for CLint,h of CYP3A4 substrates by Monte Carlo simulation. Using the reported variability of the AUC of omeprazole, we previously used this method to estimate the variability of the hepatic intrinsic clearance of CYP2C19 substrates (CLint,h,cyp2C19) as 66% and 56% for subjects with CYP2C19*1/*1 and CYP2C19*1/*2 or CYP2C19*1/*3, respectively.15 Using these CV values, the AUC variabilities of other CYP2C19 substrates have been successfully estimated.15

    • Identifying populations sensitive to environmental chemicals by simulating toxicokinetic variability

      2017, Environment International
      Citation Excerpt :

      CV of abundance has been estimated at 31% for CYP3A4 and 36% for CYP2E1 (Lipscomb et al., 2003). CV of isozyme-specific CLint has been estimated at 33% for CYP3A4 (Kato et al., 2010); 60–70% for CYP2D6 (Chiba et al., 2012); 66% in extensive CYP2C19 metabolizers, and 26% in poor CYP2C19 metabolizers (Chiba et al., 2014). HTTK-Pop's assumption of 30% CV in overall CLint may therefore be reasonable for compounds primarily metabolized by CYP3A4 or 2E1, but may be an underestimate for compounds primarily metabolized by CYP2D6 or 2C19.

    • Prediction of inter-individual variability on the pharmacokinetics of CYP1A2 substrates in non-smoking healthy volunteers

      2016, Drug Metabolism and Pharmacokinetics
      Citation Excerpt :

      Because drugs with a low hepatic first-pass effect minimize the variability of that effect, they can be considered to estimate the CV of CLint,h,1A2 more accurately. The inter-individual variability of other CYPs that have been reported by our group are 33% CV for CYP3A4 [6], 60% CV for CYP2D6 in EM [7], 66% CV for CYP2C19 in EM [59], and 18.1% CV for CYP2C9 in EM. The inter-individual variability of CYP1A2 (55%) was similar to that of CYP2D6 but otherwise relatively high among CYPs.

    View all citing articles on Scopus

    Software supported in part by KAKENHI (grant no. 24590210) was used in the present analysis.

    View full text